Effects of Salmeterol on Walking Capacity in Patients With COPD

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to test the following hypothesis:

The acute changes in exercise tolerance during the endurance shuttle walk will be greater with salmeterol compared to placebo in patients with chronic obstructive pulmonary disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Collaborator: GlaxoSmithKline
• Treatments: Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• age > 50 years

• smoking history > 10 packs/year

• FEV1 < 70% of predicted and FEV1/FVC < 70%.

Exclusion Criteria:

• respiratory exacerbation within the 2 months preceding the study

• history of asthma

• significant O2 desaturation (SaO2 < 85%) at rest or during exercise

• presence of another pathology that could influence exercise tolerance.